Faron Historical Income Statement

FARN Stock

210.00 2.00 0.96%

Historical analysis of Faron Pharmaceuticals income statement accounts such as Selling General Administrative of 10.5 M or Other Operating Expenses of 34.5 M can show how well Faron Pharmaceuticals Oy performed in making a profits. Evaluating Faron Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Faron Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Faron Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Faron Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Faron Income Statement Analysis

Faron Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Faron Pharmaceuticals shareholders. The income statement also shows Faron investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Faron Pharmaceuticals Income Statement Chart

At this time, Faron Pharmaceuticals' Interest Expense is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 10.5 M in 2025, despite the fact that Operating Income is likely to grow to (24.4 M).

Interest Expense Selling General Administrative Other Operating Expenses Operating Income Research Development Total Operating Expenses

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Faron Pharmaceuticals. It is also known as Faron Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from Faron Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Faron Pharmaceuticals Oy is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Faron Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Faron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2022	2023	2024	2025 (projected)
Interest Expense	1.4M	2.2M	2.5M	2.6M
Depreciation And Amortization	300K	197K	226.6K	185.2K

Interest Expense Depreciation And Amortization

Faron Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Net Income From Continuing Ops	Tax Provision	Net Interest Income	Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.43	0.76	0.64	-0.68	-0.68	0.66	-0.67	0.64	-0.67	-0.37	-0.67	0.37	-0.13	-0.67	-0.62	-0.43	-0.81	0.81	-0.16
Interest Expense	0.43		0.81	0.83	-0.73	-0.73	0.6	-0.73	0.83	-0.76	-0.97	-0.76	0.97	-0.32	-0.76	-0.61	-0.99	-0.37	0.77	-0.75
Selling General Administrative	0.76	0.81		0.93	-0.89	-0.89	0.81	-0.89	0.93	-0.9	-0.75	-0.9	0.73	-0.34	-0.9	-0.79	-0.81	-0.69	0.88	-0.58
Other Operating Expenses	0.64	0.83	0.93		-0.97	-0.97	0.9	-0.97	1.0	-0.98	-0.79	-0.98	0.76	-0.38	-0.98	-0.9	-0.83	-0.63	0.81	-0.59
Operating Income	-0.68	-0.73	-0.89	-0.97		1.0	-0.96	1.0	-0.97	1.0	0.71	1.0	-0.67	0.41	1.0	0.94	0.75	0.68	-0.8	0.39
Ebit	-0.68	-0.73	-0.89	-0.97	1.0		-0.96	1.0	-0.97	1.0	0.72	1.0	-0.67	0.39	1.0	0.94	0.75	0.67	-0.8	0.39
Research Development	0.66	0.6	0.81	0.9	-0.96	-0.96		-0.96	0.91	-0.95	-0.59	-0.95	0.54	-0.36	-0.95	-0.91	-0.63	-0.62	0.75	-0.23
Ebitda	-0.67	-0.73	-0.89	-0.97	1.0	1.0	-0.96		-0.97	1.0	0.72	1.0	-0.67	0.4	1.0	0.94	0.76	0.67	-0.8	0.39
Total Operating Expenses	0.64	0.83	0.93	1.0	-0.97	-0.97	0.91	-0.97		-0.98	-0.79	-0.98	0.76	-0.38	-0.98	-0.9	-0.83	-0.63	0.81	-0.59
Income Before Tax	-0.67	-0.76	-0.9	-0.98	1.0	1.0	-0.95	1.0	-0.98		0.75	1.0	-0.7	0.41	1.0	0.93	0.79	0.66	-0.81	0.42
Total Other Income Expense Net	-0.37	-0.97	-0.75	-0.79	0.71	0.72	-0.59	0.72	-0.79	0.75		0.75	-0.96	0.23	0.75	0.56	0.99	0.24	-0.71	0.64
Net Income	-0.67	-0.76	-0.9	-0.98	1.0	1.0	-0.95	1.0	-0.98	1.0	0.75		-0.71	0.41	1.0	0.93	0.79	0.66	-0.81	0.41
Income Tax Expense	0.37	0.97	0.73	0.76	-0.67	-0.67	0.54	-0.67	0.76	-0.7	-0.96	-0.71		-0.29	-0.7	-0.52	-0.96	-0.31	0.69	-0.69
Gross Profit	-0.13	-0.32	-0.34	-0.38	0.41	0.39	-0.36	0.4	-0.38	0.41	0.23	0.41	-0.29		0.39	0.58	0.32	0.44	-0.44	0.18
Net Income From Continuing Ops	-0.67	-0.76	-0.9	-0.98	1.0	1.0	-0.95	1.0	-0.98	1.0	0.75	1.0	-0.7	0.39		0.93	0.78	0.66	-0.81	0.42
Tax Provision	-0.62	-0.61	-0.79	-0.9	0.94	0.94	-0.91	0.94	-0.9	0.93	0.56	0.93	-0.52	0.58	0.93		0.62	0.72	-0.75	0.36
Net Interest Income	-0.43	-0.99	-0.81	-0.83	0.75	0.75	-0.63	0.76	-0.83	0.79	0.99	0.79	-0.96	0.32	0.78	0.62		0.36	-0.79	0.64
Interest Income	-0.81	-0.37	-0.69	-0.63	0.68	0.67	-0.62	0.67	-0.63	0.66	0.24	0.66	-0.31	0.44	0.66	0.72	0.36		-0.73	0.2
Reconciled Depreciation	0.81	0.77	0.88	0.81	-0.8	-0.8	0.75	-0.8	0.81	-0.81	-0.71	-0.81	0.69	-0.44	-0.81	-0.75	-0.79	-0.73		-0.39
Selling And Marketing Expenses	-0.16	-0.75	-0.58	-0.59	0.39	0.39	-0.23	0.39	-0.59	0.42	0.64	0.41	-0.69	0.18	0.42	0.36	0.64	0.2	-0.39

Click cells to compare fundamentals

Faron Pharmaceuticals Account Relationship Matchups

Faron Pharmaceuticals income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	283K	306K	300K	197K	226.6K	185.2K
Interest Expense	389K	235K	1.4M	2.2M	2.5M	2.6M
Selling General Administrative	4.9M	9.9M	7.5M	8.7M	10.0M	10.5M
Other Operating Expenses	16.7M	21.1M	27.4M	28.6M	32.9M	34.5M
Operating Income	(16.7M)	(21.1M)	(27.4M)	(28.6M)	(25.7M)	(24.4M)
Ebit	(16.8M)	(21.0M)	(27.4M)	(28.6M)	(25.7M)	(24.4M)
Research Development	13.9M	17.4M	20.7M	19.5M	22.5M	12.5M
Ebitda	(16.5M)	(20.7M)	(27.1M)	(28.4M)	(25.5M)	(24.3M)
Total Operating Expenses	16.7M	21.1M	27.4M	28.6M	32.9M	34.5M
Income Before Tax	(16.9M)	(21.2M)	(28.7M)	(30.9M)	(27.8M)	(26.5M)
Total Other Income Expense Net	(280K)	(70K)	(1.3M)	(2.4M)	(2.1M)	(2.0M)
Net Income	(16.9M)	(21.2M)	(30.0M)	(30.9M)	(27.8M)	(26.5M)
Income Tax Expense	11K	10K	16K	1.3M	1.5M	1.6M
Net Income From Continuing Ops	(16.9M)	(21.2M)	(28.7M)	(30.9M)	(27.8M)	(26.5M)
Net Income Applicable To Common Shares	(13.3M)	(16.9M)	(21.2M)	(28.7M)	(25.9M)	(24.6M)
Net Interest Income	(282K)	(245K)	(1.3M)	(2.4M)	(2.1M)	(2.0M)
Interest Income	9K	2K	11K	230K	207K	125K
Reconciled Depreciation	283K	307K	300K	346K	397.9K	259.3K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
V	Visa Class A
C	Citigroup

Additional Tools for Faron Stock Analysis

When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC